SYN002
Prevention of Cytomegalovirus (CMV) infection in transplant recipients
Pre-clinicalActive
Key Facts
Indication
Prevention of Cytomegalovirus (CMV) infection in transplant recipients
Phase
Pre-clinical
Status
Active
Company
About Synklino
Synklino is a preclinical-stage biotech targeting a critical unmet need in transplant medicine: cytomegalovirus (CMV) infection. The company is developing SYN002, a therapeutic aimed at eliminating CMV from donor organs prior to transplantation (ex vivo) or treating recipients afterward (in vivo), with proof-of-concept data recently published. Founded by experienced life science veterans, Synklino operates as a private, pre-revenue company leveraging a focused scientific approach and an international network to advance its pipeline for chronic viral infections.
View full company profile